DAVID MEEK (born September 12, 1963) is an American businessman. He has over 25 years of international experience in the pharmaceutical industry. He held various global executive positions in major pharmaceutical and biotechnology companies.[1]

In July 2016, the Board of Directors of Ipsen (Euronext: IPN), a French pharmaceutical company, appointed David Meek as Chief Executive Officer.


Early life

David Meek holds a Bachelor of Arts (B.A.) in Business Administration and Management from the University of Cincinnati.


Career

In January 2001, he began his career as National Field Sales Director CNS and Primary Care in Janssen Biotech, Pharmaceutical Companies of Johnson & Johnson (until December 2004 based in Titusville, NJ).

He later joined Novartis Pharmaceuticals ($NVS), where he ran the company's respiratory and dermatology franchise in Switzerland (January 2005 – June 2007) before heading up operations in Canada (CEO & President, June 2007 - January 2010) [2] and later running its oncology biz in Europe (January 2010 - August 2012).

He’s not only been in the pharmaceutical industry, however, and before joining Baxter he was the COO of Endocyte ($ECYT) from August 2012 to July 2014, based in Indianapolis.[3][4][5]

He later joined Baxter International Inc. as Head of Oncology division (July 2014 - June 2015, based in Cambridge, Massachusetts).

He was Executive Vice-President and President of the oncology division of Baxalta Inc., which was recently acquired by Shire (July 2015 – July 2016 based in Cambridge, MA).[6][7][8]

In July 2016, the Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY), has appointed David Meek as Chief Executive Officer, effective July 18, 2016. David Meek will be based at Ipsen’s headquarters in Boulogne-Billancourt, a suburb of Paris.[9][10][11][12][13]

On June 7, 2017 the Shareholders’ Meeting approved the appointment of David Meek, Margaret A. Liu and Carol Stuckley as Directors for a term of four years.[14]

On July 10, 2017 less than a year into the job, Davis Meek laid out a strategy to acquire cancer, neurological and rare-disease treatments. So Ipsen aims for sales to rise to more than 2.5 billion euros in 2020 from almost 1.7 billion euros last year.[15]


References


External links

-   - David Meek - National Pharmaceutical Congress Part 1 - Toronto, March 25, 2009
-   - David Meek - National Pharmaceutical Congress Part 2 - Toronto, March 25, 2009
-   - David Meek - CEO Ipsen since July 2016

Category:Living people Category:University of Cincinnati alumni Category:Businesspeople in the pharmaceutical industry Category:American health care chief executives Category:1963 births

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]